Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
|Articles|November 1, 2003
Insurers' losses are 'greatest contributor' to rising rates
Author(s)Bob Gatty
Congress has been told by its chief investigative agency that increasing medical malpractice awards, indeed, are contributing to skyrocketing premium costs for many physicians, but that fact is not having a widespread impact on patients' access to health care.
Advertisement
Advertisement
Related to this article
From emerging therapies to earlier intervention and psychosocial support, Dermatology Times looks back at key alopecia areata developments in 2026.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
Guselkumab met primary and major secondary endpoints in the phase 4 STAR study, improving axial PsA symptoms and MRI-confirmed inflammation.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.
Three experimental hair loss mechanisms are moving through late-stage trials for the first time in decades, and the data are worth knowing before patients ask.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
Alopecia Areata Awareness Month: 2026 in Review
3
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
4
Lauren Miller, PA-C: Being a PA Has Never Meant Being Just One Thing
5